Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: A pediatric report and literature review

Pediatric Critical Care Medicine

Volumn 12, Issue 2, 2011, Pages

  Harambat, Jérôme ^a,c   Lamireau, Delphine ^b   Delmas, Yahsou ^b,c   Ryman, Anne ^b   Llanas, Brigitte ^a,c   Brissaud, Olivier ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HÔPITAL PELLEGRIN   (France)

^c Centre de Référence Maladies Rénales Rares du Sud Ouest SORARE   (France)

Author keywords

ADAMTS13; child; rituximab; thrombotic microangiopathy; thrombotic thrombocytopenic purpura

Indexed keywords

FRESH FROZEN PLASMA; GENTAMICIN; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; RITUXIMAB; VANCOMYCIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACQUIRED ADAMTS13 DEFICIENCY; ACUTE KIDNEY FAILURE; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; CHILD; CONFUSION; EMERGENCY WARD; ENZYME DEFICIENCY; FEVER; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; LUNG HEMORRHAGE; MALE; MULTIPLE ORGAN FAILURE; NEUROLOGIC DISEASE; PALLOR; PETECHIA; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; URINALYSIS; VOMITING;

EID: 79953094069     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181e89f8f     Document Type: Article

References (25)

1. Loirat C, Veyradier A, Girma JP, et al: Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children. Semin Thromb Hemost 2006; 32:90-97
2. Robson WL, Tsai HM: Thrombotic thrombocy-topenic purpura attributable to von Willebrand factor-cleaving protease inhibitor in an 8-year-old boy. Pediatrics 2002; 109:322-325 (Pubitemid 34126877)
3. Ashida A, Nakamura H, Yoden A, et al: Successful treatment of a young infant who de-veloped high-titer inhibitors against VWF-cleaving protease (ADAMTS-13): Important discrimination from Upshaw-Schulman syn-drome. Am JHematol 2002; 71:318-322 (Pubitemid 35396951)
4. Horton TM, Stone JD, Yee D, et al: Case series of thrombotic thrombocytopenic pur-pura in children and adolescents. J Pediatr Hematol Oncol 2003; 25:336-339 (Pubitemid 36506226)
5. Schneppenheim R, Budde U, Hassenpflug W, et al: Severe ADAMTS-13 deficiency in child-hood. Semin Hematol 2004; 41:83-89
6. Allford SL, Hunt BJ, Rose P, et al: Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120:556-573
7. Giulino LB, Bussel JB, Neufeld EJ, et al: Treatment with rituximab in benign and ma-lignant hematologic disorders in children. J Pediatr 2007; 150:338-344, 344.e1
8. Fakhouri F, Vernant JP, Veyradier A, et al: Efficiency of curative and prophylactic treat-ment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: A study of 11 cases. Blood 2005; 106:1932-1937 (Pubitemid 41291703)
9. Scully M, Cohen H, Cavenagh J, et al: Remis-sion in acute refractory and relapsing throm-botic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br JHaema-tol 2006; 136:451-461 (Pubitemid 46046304)
10. Curtillet C, Poullin P, Doré E, et al: Paediatric case report of an acquired autoimmune thrombotic thrombocytopenic purpura. Arch Pediatr 2006; 13:1521-1524 (Pubitemid 44895638)
11. Albaramki JH, Teo J, Alexander SI: Ritux-imab therapy in two children with autoImmune thrombotic thrombocytopenic pur-pura. Pediatr Nephrol 2009; 24:1749-1752
12. Gerristen HE, Turecek PL, Schwartz HP, et al: Assay of von Willebrand Factor (vWF)-cleaving protease based on decreased colla-gen binding affinity of degraded vWF. Thromb Haemost 1999; 82:1386-1389
13. Taylor FB Jr, Toh CH, Hoots WK, et al: Scien-tific Subcommittee on Disseminated Intravas-cular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and labo-ratory criteria, and a scoring system for dis-seminated intravascular coagulation. Thromb Haemost 2001; 86:1327-1330
14. Coppo P, Bengoufa D, Veyradier A, et al: Severe ADAMTS13 deficiency in adult idio-pathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine 2004; 83:233-244 (Pubitemid 38955446)
15. George JN: The thrombotic thrombocytope-nic purpura and hemolytic uremic syn-dromes: Evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007. Kidney Int 2009; 112:S52-S54
16. Shumak KH, Rock GA, Nair RC: Late relapses in patients successfully treated for throm-botic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med 1995; 122: 569-572
17. Tuncer HH, Oster RA, Huang ST, et al: Pre-dictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: A sin-gle-institution experience. Transfusion 2007; 47:107-114 (Pubitemid 46006317)
18. Zheng XL, Kaufman RM, Goodnough LT, et al: Effect of plasma exchange on plasma AD-AMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-4049 (Pubitemid 38685342)
19. Ferrari S, Scheiflinger F, Rieger M, et al: Prognostic value of anti-ADAMTS 13 anti-body features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic mi-croangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109:2815-2822 (Pubitemid 46482076)
20. Peyvandi F, Lavoretano S, Palla R, et al: AD-AMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired throm-botic thrombocytopenic purpura during re-mission. Haematologica 2008; 93:232-239 (Pubitemid 351397711)
21. Rizvi MA, Vesely SK, George JN, et al: Com-plications of plasma exchange in 71 consec-utive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion 2000; 40:896-901
22. Rao A, Kelly M, Musselman M, et al: Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoImmune cytopenias. Pediatr Blood Cancer 2008; 50:822-825 (Pubitemid 351354792)
23. El-Hallak M, Binstadt BA, Leichtner AM, et al: Clinical effects and safety of rituximab for treatment of refractory pediatric autoImmune diseases. J Pediatr 2007; 150:376-382 (Pubitemid 46437325)
24. Chaumais MC, Garnier A, Chalard F, et al: Fatal pulmonary fibrosis after rituximab ad-ministration. Pediatr Nephrol 2009; 24: 1753-1755
25. Sadler JE: Von Willebrand factor, AD-AMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112:11-18